The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Activity of Dendrimer−Methotrexate Conjugates on Methotrexate-Sensitive and -Resistant Cell Lines
Abstract
Dendritic nanostructures can play a key role in drug delivery, due to the high density and variety of surface functional groups that can facilitate and modulate the delivery process. We have investigated the effect of dendrimer end-functionality on the activity of polyamido amine (PAMAM) dendrimer-methotrexate (MTX) conjugates in MTX-sensitive and MTX-resistant human acute lymphoblastoid leukemia (CCRF-CEM) and Chinese hamster ovary (CHO) cell lines. Two amide-bonded PAMAM dendrimer-MTX conjugates were prepared using a dicyclohexylcarbodiimide (DCC) coupling reaction: one between a carboxylic acid-terminated G2.5 dendrimer and the amine groups of the MTX (conjugate A) and another between an amine-terminated G3 dendrimer and the carboxylic acid group of the MTX (conjugate B). Our studies suggest that conjugate A showed an increased drug activity compared to an equimolar amount of free MTX toward both sensitive and resistant cell lines, whereas conjugate B did not show significant activity on any of the cell lines. Despite substantially impaired MTX transport by MTX-resistant CEM/MTX and RII cells, conjugate A showed sensitivity increases of approximately 8- and 24-fold (based on IC50 values), respectively, compared to free MTX. Co-incubation of the cells with adenosine and thymidine along with either conjugate A or MTX resulted in almost complete protection, suggesting that the conjugate achieves its effect on dihyrofolate reductase (DHFR) enzyme through the same mechanism as that of MTX. The differences in cytotoxicity of these amide-bonded conjugates may be indicative of differences in the intracellular drug release from the cationic dendrimer (conjugate B) versus the anionic dendrimer (conjugate A), perhaps due to the differences in lysosomal residence times dictated by the surface functionality. These findings demonstrate the feasibility of using dendrimers as drug delivery vehicles for achieving higher therapeutic effects in chemotherapy, especially in drug-resistant cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polyester Dendritic Systems for Drug Delivery Applications: In Vitro and In Vivo Evaluation
Padilla De Jesús, O. L., Ihre, H. R., Gagne, L., Fréchet, J. M. J., & Szoka, F. C. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010103m · Cited by 507
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Astruc, D., Boisselier, E., & Ornelas, C. (2010) · Chemical Reviews · doi:10.1021/cr900327d · Cited by 1,844
Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications
Menjoge, A. R., Kannan, R. M., & Tomalia, D. A. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.009 · Cited by 795
Self-citationDendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues
Pandita, D., Madaan, K., Kumar, S., Poonia, N., & Lather, V. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.130965 · Cited by 679
Biomedical applications of dendrimers: a tutorial
Mintzer, M. A., & Grinstaff, M. W. (2011) · Chem. Soc. Rev. · doi:10.1039/b901839p · Cited by 671
Dendrimers as Carriers for Delivery of Chemotherapeutic Agents
Medina, S. H., & El-Sayed, M. E. H. (2009) · Chemical Reviews · doi:10.1021/cr900174j · Cited by 669
Harish, V., Tewari, D., Gaur, M., Yadav, A. B., Swaroop, S., Bechelany, M., & Barhoum, A. (2022) · Nanomaterials · doi:10.3390/nano12030457 · Cited by 623
Dendrimers as versatile platform in drug delivery applications
Svenson, S. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.023 · Cited by 570
Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
Self-citationTherapeutic and diagnostic applications of dendrimers for cancer treatment☆
WOLINSKY, J., & GRINSTAFF, M. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.012 · Cited by 540
PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy
Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Ezzati Nazhad Dolatabadi, J., & Hamblin, M. R. (2018) · Applied Materials Today · doi:10.1016/j.apmt.2018.05.002 · Cited by 487
Advanced drug delivery systems: Nanotechnology of health design A review
Safari, J., & Zarnegar, Z. (2014) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2012.12.009 · Cited by 429
The effect of surface functionality on cellular trafficking of dendrimers
Perumal, O. P., Inapagolla, R., Kannan, S., & Kannan, R. M. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.038 · Cited by 379
Self-citationSingh, P., Gupta, U., Asthana, A., & Jain, N. K. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800125u · Cited by 329
Kaminskas, L. M., Kelly, B. D., McLeod, V. M., Sberna, G., Boyd, B. J., Owen, D. J., & Porter, C. J. H. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1001872 · Cited by 64
Metadata
- Authors
- Gurdag, S., Khandare, J., Stapels, S., Matherly, L. H., & Kannan, R. M.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-02-28
- Volume
- 17
- Issue
- 2
- Pages
- 275-283
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2141276842
- Cited by
- 165
- References
- 1
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.